Nichole Tucker

The novel first-in-class small molecule inhibitor of HIF-2α, PT2385 demonstrated the ability to stabilize disease with tolerable safety in patients with von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC) and non-renal tumors, according to results presented in a poster during the 21st Annual Meeting of the Society of Urologic Oncology (SUO).

A subanalysis of the PRIMA/ENGOT-OV26/GOG-3012 trial found that quality of life according to patient-reported outcomes was not reduced despite treatment toxicities in those with ovarian, primary peritoneal, or fallopian tube cancer treated with niraparib versus placebo.